RAM
TBPH icon

Riggs Asset Management’s Theravance Biopharma TBPH Stock Holding History

Riggs Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-114
Closed -$967 – 699
2024
Q2 		$967 Sell
114
-3
-3% -$27 ﹤0.01% 440
2024
Q1 		$1.05K Buy
+117
New +$1.08K ﹤0.01% 413

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Riggs Asset Management's TBPH Position: Q3 2024 in Review

Riggs Asset Management sold out of Theravance Biopharma (TBPH) in Q3 2024, closing a stake of 114 shares — an estimated $967 sold.

Riggs Asset Management first reported a position in TBPH in Q1 2024 and held it in 2 quarters. The position peaked at $1.05K in Q1 2024. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2024.

  • Riggs Asset Management reported no remaining Theravance Biopharma position as of Q3 2024 after selling out during the quarter.
  • Riggs Asset Management sold 114 Theravance Biopharma shares in Q3 2024, an estimated $967.
  • Riggs Asset Management first reported a position in Theravance Biopharma in Q1 2024 and held it in 2 quarters.
  • Riggs Asset Management's Theravance Biopharma position peaked at $1.05K in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2024.

Based on Riggs Asset Management's 13F filing for Q3 2024, filed 24 Oct 2024.